Multi-level Interventions to Manage Co-morbidities Among Black Breast and Prostate Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- Feasibility of study protocol
研究概览
简要总结
Black cancer patients tend to have worse outcomes than White cancer patients. Some of this disparity may be due to comorbidities. The purpose of this study is to improve management of co-morbidities among cancer patients in order to improve cancer outcomes and improve health equity.
Comorbidities such as diabetes and hypertension can complicate cancer treatment or can make it difficult to reach optimal health after treatment. This study will offer additional support and tools to manage cancer patient's health needs. First, the study will use a mobile health application, managed by a company called Welldoc, to monitor patient progress in real time and to provide ongoing guidance. Second, the study will connect patients with a Community Health Worker who will speak with them weekly to discuss self-care information, including medical scheduling or appointment needs, and assist with daily self-monitoring of blood pressure and/or blood glucose monitoring. Lastly, an oncology nurse will monitor reported health and triage any medical needs and whether additional medical care is needed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Black women with a diagnosis of stage 0-IV breast cancer and within a month of treatment initiation or with 6+ months of treatment left OR Black men with a history of prostate cancer who are on long-term androgen deprivation therapy;
- •Blood pressure >=120/80 OR diagnosis of diabetes
- •Individuals who develop these conditions during treatment such as those scheduled to initiate steroid-containing chemotherapy or targeted PI3K inhibitor therapies
- •Access to a smartphone and/or internet for the duration of the study.
- •Can understand and communicate in English
排除标准
- •Unwilling to participate in a 6-month study
结局指标
主要结局
Feasibility of study protocol
时间窗: Study recruitment period will be approximately 12 months
Accrual of \>50 patients into the study
Feasibility of an active management strategy for comorbidities
时间窗: Study duration will be 6 months for prostate cancer patients and duration of treatment plus one month for breast cancer patients (approximately 7 months)
\>80% recording blood pressure and/or blood glucose 3+ times per week
次要结局
- Provider perspectives on acceptability of active management of comorbidities(Beginning and end of study (approximately 18 months))
研究者
Hannah Arem
Scientific Director, Implementation Science
Medstar Health Research Institute